Immuneering IMRX
NASDAQ IMRX
$4.82 -0.22 (-4.37%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immuneering (IMRX) EV to CFO (2021 - 2026)

Analysis

Immuneering (IMRX) EV to CFO (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Immuneering 313.13 Mn 313.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.48
Mar 31, 2026 -9.99
Dec 31, 2025 -11.87
Sep 30, 2025 -4.19
Jun 30, 2025 -10.05
Mar 31, 2025 -1.34
Dec 31, 2024 -2.22
Sep 30, 2024 -1.98
Jun 30, 2024 1.89
Mar 31, 2024 -0.93
Dec 31, 2023 -11.00
Sep 30, 2023 -10.60
Jun 30, 2023 -17.47
Mar 31, 2023 -11.50
Dec 31, 2022 -1.92
Sep 30, 2022 -24.56
Jun 30, 2022 -1.55
Mar 31, 2022 -2.68
Dec 31, 2021 -7.68
Sep 30, 2021 -37.19